- Home
- INKT vs DMA Comparison
INKT vs DMA Comparison
Compare INKT & DMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INKT | DMA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 76.4M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | INKT | DMA |
|---|---|---|
| Price | $11.60 | $7.54 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 46.5K | 28.1K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $7.27 |
| 52 Week High | $76.00 | $9.15 |
Technical Indicators
Market Signals| Indicator | INKT | DMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 35.47 |
| Support Level | $10.88 | N/A |
| Resistance Level | $12.58 | $8.89 |
| Average True Range (ATR) | 1.06 | 0.22 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 26.18 | 28.21 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.